Oct 25, 2023 / 05:00PM GMT
Ed White - H. C. Wainwright & Co., LLC - Analyst
Hello, everyone, and thank you for joining the H. C. Wainwright Fourth Annual Hepatitis B Virus Virtual Conference. My name is Ed White, and I'm a senior analyst here at H. C. Wainwright covering Dynavax Technologies, ticker DVAX.
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing novel vaccines utilizing innovative adjuvant technology. HEPLISAV-B is the company's two-dose vaccine that is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 and older.
Now it is my pleasure to introduce Kelly MacDonald, CFO of Dynavax. Thanks for taking part in the conference, Kelly.
Kelly MacDonald - Dynavax Technologies Corporation - CFO & SVP
Thank you, Ed, and thank you all for joining us today. Before we begin, I'd like to recognize that the presentation contains forward-looking statements that have certain risks and uncertainties that are highlighted in our Risk Factors, in the Form 10-Q, as well as our other SEC
Dynavax Technologies Corp at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript
Oct 25, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers